Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.57 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.57 |
| ▸ | CHRNB3 | Q05901 | 3/20 | 0.57 |
| ▸ | CHRNA6 | Q15825 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15515214 | 0.88 | CHRNB2 (0.48) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL15515212 | 0.88 | CHRNB2 (0.48) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL20323805 | 0.88 | HPGD (0.63) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL20323814 | 0.88 | HPGD (0.69) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL12509435 | 0.81 | HPGD (0.54) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL102680 | 0.81 | HPGD (0.54) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL2146105 | 0.80 | CHRNB2 (0.50) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL27785354 | 0.79 | ALOX5 (0.46) | ALDH1A1POLBALOX5 | |
| Hydrochloric Acid SCHEMBL2148654 | 0.79 | CHRNB2 (0.49) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL2148647 | 0.79 | CHRNB2 (0.49) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926292-B2 | Pyridinyl derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-27 | — | — | US | disclosed |
| US-20170327483-A1 | Pyridinyl derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-16 | — | — | US | disclosed |
| EP-3002278-B1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-04-19 | — | — | EP | disclosed |
| WO-2012124696-A1 | GUANIDINE COMPOUND | アステラス製薬株式会社 (JP) | 2012-09-20 | — | — | WO | disclosed |
| US-5296479-A | Treating physiological or drug-induced psychosis or dyskinesia | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-03-22 | — | — | US | disclosed |
| US-5266572-A | Antipsychotic 1-cycloalkylpiperidines | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-11-30 | — | — | US | disclosed |
| US-5243048-A | Treatment of drug-induced or physiological psychosis or dyskinesia; side effect reduction | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-09-07 | — | — | US | disclosed |
| EP-0490962-A4 | ANTIPSYCHOTIC 1-CYCLOALKYLPIPERIDINES | — | 1993-03-03 | — | — | EP | disclosed |
| EP-0490962-A1 | ANTIPSYCHOTIC 1-CYCLOALKYLPIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-06-24 | — | — | EP | disclosed |
| US-5109002-A | ANTIPSYCHOTIC 1-CYCLOALKYLPIPERIDINES | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-04-28 | — | — | US | disclosed |
| WO-1991003243-A1 | ANTIPSYCHOTIC 1-CYCLOALKYLPIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327483-A1 | Pyridinyl derivatives, pharmaceutical compositions and uses thereof | P2RY1, PNPO, P2RY4 | CHRNB2 2064/4885CHRNA3 1107/4885CHRNA4 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.